AstraZeneca Invests $2B in Summit Therapeutics, Inks Clinical Trial Collab

AstraZeneca is teaming up with Summit Therapeutics to test its PD-1/VEGF bispecific ivonescimab alongside AstraZeneca’s antibody-drug conjugates.

$SMMT: AstraZeneca’s agreed $2B investment, dilution, GI combination study and the separate ESMO and FDA milestones.

Summit Therapeutics Inc. Common Stock · $18.22 +17.70% · Healthcare

MRC funds academic teams to screen compounds from AstraZeneca's 2 million molecule library, with up to four projects a year. Applications close 28 January 2027.

AZN's Phase 2 Liver Trial Halted, but Pipeline Advances Elsewhere InsiderWatch | insider.wizybit.com

The U.S. regulatory body has approved AstraZeneca’s Etcamah in combination with CDK4/6 inhibitors, to treat adults with HR‑positive, HER2‑negative metastatic breast cancer who are resistant to…

Reported Friday, Sep 25 - 7:05am EDT (TheFly subscription required to read more.)

AstraZeneca received European Commission approval for Trixeo Aerosphere to treat asthma in patients 12 and older whose symptoms aren't controlled by standard dual-therapy inhalers. The approval makes Trixeo the first triple-combination inhaler authorized in the EU for asthma, expanding AstraZeneca's respiratory drug portfolio.

The European Commission cleared AstraZeneca's triple-combination inhaler Trixeo Aerosphere for asthma patients aged 12 and over, extending a drug already established in COPD treatment.

On Tuesday 22 and Wednesday 23 September 2026, influential researchers from across Europe will gather at AstraZeneca’s facility in Macclesfield to present a series of lectures on the latest developmen...

The European regulator's advisory committee has recommended Alexion's gefurulimab for approval in generalised myasthenia gravis, setting up a potential first-in-class launch in the EU.

The EU medicines regulator recommended Enhertu for adjuvant use in HER2-positive early breast cancer, backed by a trial showing a 53% reduction in disease recurrence or death versus current standard care.

The FDA has cleared a new breast cancer treatment strategy that does not wait for a scan to show the disease getting worse. Etcamah, AstraZeneca’s newly approved oral breast cancer […] The post FDA Greenlights Groundbreaking Breast Cancer Treatment, And The New Pill Targets A Mutation That Can Make Cancer Drugs Stop Working appeared first on Baller Alert.

Biocatalysis is strengthening AstraZeneca's manufacture of active pharmaceutical ingredients through faster development, robust scale-up, and lower environmental impact. Case studies illustrate where biocatalysis delivers greatest value, while enabling platforms, teams, and partnerships shape its next phase. Biocatalysis is becoming a strategic manufacturing capability at AstraZeneca, enabling selective transformations under milder conditions and with the potential to reduce waste and resource…

Reported Friday, Sep 18 - 8:06am EDT (TheFly subscription required to read more.)

Reported Friday, Sep 18 - 6:31am EDT (TheFly subscription required to read more.)

At its Sept. 14 meeting the commission approved minutes, continued Bowers Park to October, approved a two‑year extension for STF 18‑275, approved East Pat Lofts and Ren 0.25 actions, and conditionally approved AstraZeneca's expansion; group‑housing zoning (PLQ) was continued to Oct. 12.